Catalyst Wire Dossier Catalyst Wire Dossier

Ensifentrine-glycopyrrolate fixed-dose combination

· Verona Pharma plc
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ensifentrine-glycopyrrolate fixed-dose combination, covering 2026-01-08 to 2026-01-08. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease [Phase 2]

See pricing